Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Chimeric Antigen Receptor T-cell Therapy
45%
CD19 chimeric Antigen Receptor T Cells
24%
Acute Lymphoblastic Leukemia
24%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
24%
CD19
22%
Relapsed or Refractory
21%
Anti-CD19 chimeric Antigen Receptor T Cells
20%
Older Adults
18%
Overall Survival
17%
T Cells
16%
Leukemia
16%
Relapsed or Refractory Acute Myeloid Leukemia
16%
CD19 CAR T Cells
13%
Pediatric
13%
CD28
13%
Cell Therapy
13%
Point-of-care
13%
Haploidentical Hematopoietic Stem Cell Transplantation
12%
B-cell Malignancies
12%
Event-free Survival
12%
Improved Outcomes
11%
Graft-versus-host Disease (GvHD)
10%
Confidence Interval
10%
Cytokine Release Syndrome
9%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
9%
Large B-cell Lymphoma
9%
Complete Remission
9%
Tisagenlecleucel
9%
CART19
9%
American Society
9%
Mitochondrial DNA mutation
9%
Clinical Response
8%
Blinatumomab
8%
Engraftment
8%
Hematopoietic Stem Cell Transplantation
8%
Clinical Trials
7%
Complete Response
7%
Non-Hodgkin Lymphoma
7%
Pediatric Patients
7%
Hematological Malignancies
7%
Glioblastoma
7%
Cell Infusion
7%
HLA-matched Donor
7%
Aggressive B-cell Lymphoma
6%
CD19+
6%
Allogeneic
6%
Marrow Transplantation
6%
Neurotoxicity
6%
Acute Leukemia
6%
Medicine and Dentistry
Chimeric Antigen Receptor T-Cell
95%
Chimeric Antigen Receptor T-Cell Immunotherapy
40%
Acute Lymphoblastic Leukemia
38%
Chimeric Antigen Receptor
30%
T Cell
26%
B Cell
23%
Acute B-Cell Lymphoblastic Leukemia
21%
B-Cell Lymphoma
17%
Leukemia
16%
Pediatrics
15%
Cell Therapy
15%
Overall Survival
15%
Non-Hodgkin Lymphoma
13%
Infusion
12%
Immunotherapy
12%
Event Free Survival
12%
Large-Cell Lymphoma
10%
Graft Versus Host Reaction
9%
Mitochondrial DNA
9%
Acute Leukemia
9%
Hematopoietic Cell
8%
Cytokine Release Syndrome
8%
Allogeneic Hematopoietic Stem Cell Transplantation
7%
Clinical Trial
7%
Hematologic Malignancy
7%
Cancer
7%
Salvage Therapy
7%
Hematopoietic Stem Cell Transplantation
7%
Precursor
6%
Neoplasm
6%
Haploidentical Hematopoietic Stem Cell Transplantation
6%
Pediatrics Patient
6%
Diseases
6%
Leukapheresis
5%
Acute Myeloid Leukemia
5%
Blinatumomab
5%
Neurotoxicity
5%
CD19 Antigen
5%
T Lymphocyte Receptor
5%
Cell Transplantation
5%
Immunology and Microbiology
Chimeric Antigen Receptor T-Cell
55%
CD19
51%
B Cell
36%
T Cell
28%
Chimeric Antigen Receptor
27%
Chimeric Antigen Receptor T-Cell Therapy
19%
Haploidentical Hematopoietic Stem Cell Transplantation
11%
Overall Survival
11%
Graft-Versus-Host Disease
10%
Immunotherapy
10%
Event Free Survival
10%
T Cell Receptor
8%
Conditioning
8%
CD28
8%
Cyclophosphamide
7%
Hematopoietic Cell
7%
Precursor
6%
Engraftment
6%
Myeloid
6%
Lineages
6%
Blinatumomab
5%
Cytokine Release Syndrome
5%